Tylenol Autism Litigation Gets New Life After Federal Appeals Court Revives 500+ Cases

For plaintiff firms monitoring emerging pharmaceutical and product liability litigation, this is one of the most significant appellate developments of 2026, as mass tort firms across the country have been sitting on tens of thousands of cases. 

While the litigation has regained momentum, plaintiffs still must establish general and specific causation, and defendants continue to maintain that the scientific evidence does not support a causal relationship. Medical organizations have also noted that no definitive scientific consensus currently establishes that prenatal acetaminophen exposure causes ASD or ADHD. 

Appeals Court Revives Tylenol Autism/ADHD Litigation

A unanimous panel of the Second U.S. Circuit Court of Appeals revived more than 500 lawsuits alleging that prenatal exposure to acetaminophen (Tylenol) contributed to autism spectrum disorder (ASD) and ADHD in children. The court held that the trial judge improperly excluded testimony from three key plaintiff experts, sending the litigation back to the district court for further proceedings.

Why this matters for mass tort firms:

• The decision reopens one of the country’s largest pharmaceutical mass torts after it appeared effectively over following the 2024 dismissal.
• The appellate court did not rule that Tylenol causes autism or ADHD. Instead, it found that the district court applied the expert evidence standard too narrowly and that portions of the plaintiffs’ scientific evidence should be considered.
• The litigation returns to Judge Denise Cote in the Southern District of New York, where defendants—including Kenvue and major retailers such as Walmart, CVS, Walgreens, Target, and Kroger—are expected to renew challenges to plaintiffs’ experts.

Practical implications for intake

This ruling is likely to trigger:

• Increased attorney advertising and claimant outreach.
• A renewed focus on preserving prenatal medical records, pharmacy records, and developmental diagnoses.
• More firms evaluating whether to reopen screening efforts that had slowed after the 2024 dismissal.

While the litigation has regained momentum, plaintiffs still must establish general and specific causation, and defendants continue to maintain that the scientific evidence does not support a causal relationship. Medical organizations have also noted that no definitive scientific consensus currently establishes that prenatal acetaminophen exposure causes ASD or ADHD.

Other related developments mass tort attorneys should watch

1. State-level litigation may expand

The federal appeal follows increasing state-level activity surrounding prenatal acetaminophen warnings. State actions—including consumer protection litigation—could create additional filing opportunities outside the federal MDL.

2. Science and expert testimony remain the battleground

The appellate opinion focused almost entirely on the admissibility of expert testimony rather than causation itself. Going forward, expect intensive litigation over epidemiological studies, expert methodologies, and Daubert standards before any bellwether trials are scheduled.

3. Potential surge in case inventory

Industry observers expect plaintiff firms that paused intake after the federal dismissal to resume advertising and screening. If additional plaintiffs enter the litigation, the inventory could expand substantially beyond the current 500-plus revived cases.

National Record Retrieval is here to help!

Don’t forget, the NRR team can assist with record retrieval, claims data, and record review requests for any firm’s Tylenol cases. Please reach out to the National Record Retrieval Team with any questions or assistance needed. 

You can read more about the news here: 

US appeals court revives hundreds of private lawsuits linking Tylenol to autism – Reuters

Tylenol-Maker Kenvue Must Face Autism Lawsuits, Court Says – BloombergLaw

Federal court revives 550 lawsuits linking Tylenol to autism: 5 things to know – Becker’s Hospital Review

US court revives lawsuits linking painkiller Tylenol to autism– Financial Times

You can also reference the full 64-page decision here.